Belimumab in primary antiphospholipid syndrome

A. Yazıcı,B. Yazirli,D. Erkan

DOI: https://doi.org/10.1177/0961203316682102

IF: 2.858

2017-09-01

Lupus

Abstract:Sir, Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and/ or pregnancy morbidity with persistently positive antiphospholipid antibodies (aPL). Patients with aPL may also experience thrombocytopenia, cardiac valve disease, nephropathy, skin ulcer, or cognitive dysfunction, which are collectively known as non-criteria manifestations of APS. Anticoagulation is still the standard of care for the management of APS patients. However, recent studies, based on newly understood mechanisms, suggest that novel approaches that target new immunomodulatory pathways, can be considered in the management of aPL-positive patients. Based on in vitro experience, B cells are involved in aPL-related clinical events. B-cell activating factor (BAFF), also known as B lymphocyte stimulator (BLyS), blockade can prevent disease onset and prolong survival in murine APS. The efficacy of rituximab, a chimeric monoclonal antibody directed against CD20, has been reported in APS patients with non-criteria manifestations, and in catastrophic APS. Belimumab is another anti-Bcell agent, i.e. BLyS-neutralizing monoclonal antibody that inhibits the binding of soluble circulating BLyS to its target receptors on B cells; however, no data exist on the use of belimumab in APS patients. Thus, we want to describe our experience with two primary APS patients who received belimumab (10mg/kg) for an aPL-related manifestation (Table 1). Our first patient received belimumab due to recurrent diffuse alveolar hemorrhage (lung biopsy demonstrated necrotizing neutrophilic capillaritis 52 months prior to belimumab) requiring moderate dose steroids and worsening ground glass opacities. After six months, there was no new flare and he was able to taper the prednisone dose from 20mg to off; after 17 months, belimumab was stopped as he was clinically stable (only two hemoptysis episodes during viral infections); however, there was no significant radiologic improvement on the ground glass opacities. Our second patient received belimumab for recurrent skin ulcers (skin biopsy demonstrated primary microthrombosis-related ischemic panniculitis nine months prior to belimumab). After four months, the first skin ulcer completely healed and she was able to taper the prednisone from 40mg to off; however, after six months, given an infection on the biopsy side along the borders of the second ulcer belimumab was stopped. There was no significant change in aPL titers in both patients. Based on our knowledge, this is the first report of belimumab use in primary APS patients. The presentation of our patients was not consistent with another systemic autoimmune disease, e.g. systemic lupus erythematosus or vasculitis, given the lack of clinical and serological markers of these diseases, and patients’ history of APS with positive lupus anticoagulant test, moderate-to-high titer aPL enzyme-linked immunosorbent assays, and concomitant medium-to-large vessel thrombosis. Despite the lack of complete response, both patients had clinical improvement and they were able to stop corticosteroids. Thus, similar to rituximab, belimumab may have a role in the management of aPL-positive patients with microthrombotic manifestations.